Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Boosts Revenue by Out-Licensing Patented Technology to Third-Party Partners

High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018 LXRP’s technology is patented in the U.S. and Australia; company has national/regional filings pending in 44 countries Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) generates revenue by out-licensing […]

Cache Elite Inc. (ILUS) Brings Human Interaction Back into Online Travel Services Through TripWitz

TripWitz offers innovative services in the online travel market Free online help from specialist travel agents Travel services offered to more than 20,000 global destinations In recent years, online travel agencies have become more impersonal and less user-friendly, offering endless permutations for flights, accommodation, activities and transportation that have turned vacation planning into a nightmare. […]

Skinvisible, Inc.’s (SKVI) Patented Polymer Delivery Technology Could Take CBD Products to the Next Level

Skinvisible already develops hemp-based products and is expanding its product line of cannabis-based topical product market Research verifies its Invisicare® technology improves the penetration rate and boosts the availability of the cannabis ingredients in both topical and transdermal products Skinvisible has entered a strategic partnership with Canopy Growth Corporation for the sale of its product […]

 

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

April 16, 2026

Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides  both an encouraging clinical update from its phase 3 FLASH2 study and positive comparative clinical results for its HyBryte therapy, reinforcing the company’s focus […]

Rotate your device 90° to view site.